PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used
as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of …

Background Erlotinib is registered for treatment of all patients with advanced non-small-cell
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …

19000 Background: Erlotinib significantly improved survival and quality of life while delaying
symptom progression compared with placebo in patients (pts) with relapsed NSCLC …

Evaluation of: Herbst RS, Prager D, Hermann R et al.: TRIBUTE: a Phase III trial of erlotinib
hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in …

Abstract Purpose: To describe the Food and Drug Administration (FDA) review and approval
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …

Aims: The efficacy of erlotinib (Tarceva, Roche Products, Dee Why, Australia) has been
demonstrated in patients with advanced non‐small‐cell lung cancer (NSCLC). Tarceva lung …

Purpose This is a phase II, multicenter, open-label study of chemotherapy-naïve patients
with non–small-cell lung cancer (NSCLC) and age≥ 70 years who were treated with …

Background: Erlotinib and gefitinib are epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs). They have the same mechanism of action and very similar side …

7536 Background: Patients (pts) with advanced NSCLC and PS 2 have an inferior survival
compared with good PS pts. Single agent and combination chemotherapy have been used …

Purpose This phase II study evaluated efficacy of single-agent erlotinib for chemotherapy-
naïve patients with advanced/metastatic NSCLC who were ineligible for platinum doublets …